[Cardiac involvement in connective tissue disease: the example of systemic lupus erythematosus].
When we think of cardiac affection in the context of systemic lupus erythematosus (SLE), we usually refer to pericarditis first. As frequent as this affection is, it is actually not the only cardio-vascular problem that occurs with this systemic inflammatory disease. Are the cardiac events--ranging from multiple heart valve involvements to increased cardiovascular risks--clinically significant? And are they involving a specific follow-up, treatment or support? We are therefore trying to evaluate these questions in order to give some recommendations to any practitioners following up a lupus patient, or a patient suffering from any other inflammatory systemic disease.
Chappuis
S
S
Service d'immunologie et d'allergie, CHUV, 1011 Lausanne. samuel.chappuis@chuv.ch
Vogt
P
P
Petitpierre
S
S
Leimgruber
A
A
Spertini
F
F
Bart
P A
PA
D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D001022:Aortic Valve Insufficiency / Q000175:diagnosis / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D003937:Diagnosis, Differential; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D009205:Myocarditis / Q000175:diagnosis / Q000209:etiology; D010493:Pericarditis / Q000175:diagnosis / Q000209:etiology; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D000974:Antibodies, Antinuclear; D015415:Biomarkers; D005938:Glucocorticoids